VC-01™ Combination Product

Developed for: type 1 diabetes mellitus
Investigated by: California Institute for Regenerative Medicine (CIRM) · ViaCyte

today NCT02239354 · Ph 1/2

2015201620172018201920202021202220232024202520262027

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 1/2	NCT02239354	Sep 2014 → Dec 2017	type 1 diabetes mellitus	ViaCyte	Terminated	No outcome recorded

Every value below carries the sentence it was read from. 1 source stands behind the page.

Field	Value	Cited text
Known as	VC-01 Combination Product	ClinicalTrials.gov intervention name — accepted as the source's own label NCT02239354 ↗
Route	Subcutaneous	“implanted subcutaneously in subjects with Type 1 Diabetes” NCT02239354 ↗